Clinical Pipeline

Sort by:

Indication

Molecule

Indication

Study

Line & Regimen

Indication:

Kidney
Cancer

Study: 
                          
Line & Regimen : 
              Post-IO
              
                            cas + cabo vs. cabo
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                        
Line & Regimen : 

              1L
                            
                            P1b: cas + volru
P3: cas + volru vs volru vs nivo + ipi
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                        
Line & Regimen : 

              1L, 2L+
                            
                            cas, cas + cabo, cas + zim
            
Phase 1/1b
Phase 2
Phase 3

Indication:

Gastrointestinal Cancer

Study: 
                          
Line & Regimen : 
              1L
              
                            dom + zim + chemo vs.
nivo + chemo
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                        
Line & Regimen : 

              1L
                            
                            dom ± zim ± FOLFOX
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                        
Line & Regimen : 

              1L
                            
                            AB598 ± zim + chemo
            
Phase 1/1b
Phase 2
Phase 3

Indication:

Lung
Cancer

Study: 
                          
Line & Regimen : 
              1L
              
                            dom + zim + chemo vs.
pembro + chemo
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                        
Line & Regimen : 

              Stage III, unresectable, PD-L1≥1%
                            
                            dom + durvalumab vs. durvalumab
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                        
Line & Regimen : 

              1L
                            
                            dom + zim ± quemli ± chemo 
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                        
Line & Regimen : 

              1L, 2L
                            
                            dom ± zim ± sacituzumab
govitecan
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                        
Line & Regimen : 

              2L+
                            
                            AB801 ± chemo
            
Phase 1/1b
Phase 2
Phase 3

Indication:

Pancreatic Cancer

Study:

Line & Regimen :

1L
quemli + gem/nab-pac vs. gem/nab-pac

Phase 1/1b

Phase 2

Phase 3

Study:

Line & Regimen :

1L
quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac

Phase 1/1b

Phase 2

Phase 3

Indication:

Colorectal Cancer

Study:

Line & Regimen :

2L
etruma + zim + FOLFOX** vs. FOLFOX**

Phase 1/1b

Phase 2

Phase 3

Study:

Line & Regimen :

3L
etruma + zim + FOLFOX** vs. rego

Phase 1/1b

Phase 2

Phase 3

Molecule:

CASDATIFAN
(CAS)

HIF-2𝛂 Inhibitor

Indication:Kidney 
Cancer
Study:
                          
Line & Regimen :
              Post-IO

              cas + cabo vs. cabo
            
Phase 1/1b
Phase 2
Phase 3
Indication:Kidney 
Cancer
Study:
              
Line & Regimen :

              1L

              P1b: cas + volru
P3: cas + volru vs volru vs nivo + ipi
            
Phase 1/1b
Phase 2
Phase 3
Indication:Kidney 
Cancer
Study:
              
Line & Regimen :

              1L, 2L+

              cas, cas + cabo, cas + zim
            
Phase 1/1b
Phase 2
Phase 3

Molecule:

Domvanalimab
(DOM)*

FC-SILENT ANTI-TIGIT ANTIBODY

Indication:Gastrointestinal Cancer
Study:
                          
Line & Regimen :
              1L

              dom + zim + chemo vs.
nivo + chemo
            
Phase 1/1b
Phase 2
Phase 3
Indication:Gastrointestinal Cancer
Study:
              
Line & Regimen :

              1L

              dom ± zim ± FOLFOX
            
Phase 1/1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
              
Line & Regimen :

              1L

              dom + zim + chemo vs. pembro + chemo
            
Phase 1/1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
              
Line & Regimen :

              Stage III, unresectable, PD-L1≥1%

              dom + durvalumab vs. durvalumab
            
Phase 1/1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
              
Line & Regimen :

              1L

              dom + zim ± quemli ± chemo
            
Phase 1/1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
              
Line & Regimen :

              1L, 2L

              dom ± zim ± sacituzumab govitecan
            
Phase 1/1b
Phase 2
Phase 3

Molecule:

Quemliclustat
(QUEMLI)

CD73 Inhibitor Small Molecule

Indication:Pancreatic Cancer
Study:
                          
Line & Regimen :
              1L

              quemli + gem/nab-pac vs. gem/nab-pac
            
Phase 1/1b
Phase 2
Phase 3
Indication:Pancreatic Cancer
Study:
              
Line & Regimen :

              1L

              quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac
            
Phase 1/1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
              
Line & Regimen :

              1L

              dom + zim ± quemli ± chemo
            
Phase 1/1b
Phase 2
Phase 3

Molecule:

Etrumadenant
(ETRUMA)

Dual A_2a/A_2b Adenosine Receptor Antagonist Small Molecule

Indication:

Colorectal Cancer

Study:

Line & Regimen :

2L
etruma + zim + FOLFOX** vs. FOLFOX**

Phase 1/1b

Phase 2

Phase 3

Indication:

Colorectal Cancer

Study:

Line & Regimen :

3L
etruma + zim + FOLFOX** vs. rego

Phase 1/1b

Phase 2

Phase 3

Key Compounds Being Studied:

CAS

Casdatifan

HIF-2𝛂 Inhibitor

Etruma

Etrumadenant

Dual A2aR/A2bR Antagonist Small Molecule

Quemli

Quemliclustat

CD73 Inhibitor Small Molecule

Dom

Domvanalimab

anti-TIGIT mAb

Zim

Zimberelimab

anti-PD-1 mAb

Abbreviations:

cabo: cabozantinib; cas: casdatifan; chemo: chemotherapy; dom: domvanalimab; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; IO: immuno-oncology; ipi: ipilimumab; nivo: nivolumab; pembro: pembrolizumab; quemli: quemliclustat; rego: regorafenib; volru: volrustomig; zanza: zanzalintinib; zim: zimberelimab

*Gilead and Arcus share co-development and co-commercialization rights in the U.S. for domvanalimab and zimberelimab. Gilead holds commercialization rights outside of the U.S. excluding China.

**+/- e.g. bevacizumab or biosimilar, will be included for all patients in whom it is not contraindicated.

Partnerships & Collaborations

View Details

View Details

View Details

Clinical Pipeline

If interested in collaborating with Arcus, please contact [email protected]

Explore More